Increasing Intensity of On-Site Monitoring a Troubling Trend
Applied Clinical Trials
The percentage of source document verification coverage has been decreasing slightly over the past four years. Therefore, the amount of on-site time required by site monitors should also start decreasing.
SPOTLIGHT EVENTRisk-Based Monitoring – Part Two In Depth ReviewMarch 13, 2014
Cambridge, MassachusettsDownload BrochureRegister
RELATED
- What Do Risk-Based Monitoring and Patient Engagement Have in Common?
- Risk-Based Approach to Monitoring
- Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?More in Risk-Based Monitoring
In a recent blog, we presented data highlighting the trend in the percentage of source document verification coverage (i.e., percent of eCRF data targeted for SDV) and in particular observed that it has been decreasing slightly over the past four years, presumably related to early adoption of targeted, risk-based monitoring strategies. While the overall decrease has been relatively modest to-date, one might expect that the amount of on-site time required by site monitors should correspondingly start decreasing.
But this month';s Insights graph tells a different - and somewhat troubling - story. Using the Medidata Insights metrics warehouse- now comprising nearly 2,500 studies from 65 sponsor organizations - annual trends were computed and graphed of two critical monitoring efficiency metrics for Phase II/III studies:
- Monitoring on-site rate—the average number of on-site monitoring days per site per year
- SDV velocity—the average number of eCRF data points SDV'd per on-site day
The data shows that site monitors are spending increasingly more days on-site per year, and performing increasing amounts of SDV during each on-site day. This increasing burden—and cost—of site monitoring and SDV can be attributed to the increasing complexity of protocols observed in recent years. It is another reminder of the serious challenges facing clinical R&D organizations and the need to move more aggressively towards a targeted, risk-based monitoring paradigm.
Medidata is very interested to hear your take on these observed trends. Please also stay tuned as we continue to dig deeper into the Insights data through 2012.
Monitoring rates in Phase II-III trials, 2008-2011.
—Medidata Solutions, - www.mdsol.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
